StemCell Therapy

NEW YORK, Dec. 18, 2020 /PRNewswire/ --Capt. Franz Almeida has a practiced eagle's eye, honed over thousands of flight hours as a pilot. Junaid Mian, RPh, understands the challenges inherent to maintaining human health through the lens of work as a pharmacist. Both followed unique paths, which led them to angel investing. The two met at the NY chapter of the Harvard Business School.

Together they identified a yawning gap between space technology and biotechparticularly longevityverticals. They recognized that the world's economy is in the throes of change so radical that future generations will see the 21st century as a clear delineation marking a decidedly Earthbound humanity split from humanity that can freely live in and explore space.

The space economy explosion is happening, and there is no better time to invest than as early on as possible during that explosion. The latest estimates of the global space economy are well over $400 billion, and if growth continues to accelerate, many analyses point to a $1 trillion space economy just around the corner. The human longevity market is nearly as massive: A Merrill Lynch analysis revealed that the sector generates over $110 billion annually now and is growing to over $600 billion by 2025.

Without massive and ongoing investment and progress across both space technology and human longevity verticals, we will never be able to truly unlock the potential that our Solar System, and our galaxy, holds.

"A big part of why progress against aging used to be so slow was that so few experts on aging had an engineer's way of thinking. The convergence of those communities is making all the difference."

Aubrey de Grey, VP of New Technology Discovery at AgeX Therapeutics, Inc and Chief Science Officer of the SENS Research Foundation and Human Longevity advisor at SP8CEVC

And that's where Junaid Mian, RPh, and Capt. Franz Almeida comes in. The pair's varied perspectives have been a decisive match when it comes to examining the potential in merging investments across the space tech and human longevity verticals. Almeida and Mian are launching a new Rolling Fund in partnership with AngelList, with an exacting focus on solving the problem that is the future of humankind.

Under the umbrella of SP8CEVC, LPs will be able to gain exposure to deals to empower growing ventures in space technology and human longevity. Why these two rather specific categories? Simple: Moving to an economy based on the resources of our entire Solar System enables a much more substantial timeline for humanity's existence, and biotechnology work in longevity enables people to live and work in space.

The SP8CEVC partners who initially started with a traditional fund structure have chosen to use AngelList's rolling fund Reg 506(c) model to open up investment possibilities in these most critical verticals. As a series of quarterly pooled investment funds, SP8CEVC will give investors access to their deal flow quarterly on a subscription basis.

This new structure accelerates the pace of investing and, as a benefit, also helps promote innovation in those businesses.

The SP8CEVC team launched yesterday at TechCrunch Sessions: SPACE 2020. Investors and LPs interested in setting the pace for future advancement can have access to SP8CEVC's deal flow before anyone else here.

Media Contact:Franz Almeida917-287-5674 [emailprotected]

SOURCE SP8CEVC

https://www.sp8cevc.com/

Read more from the original source:
Introducing SP8CEVC: The World's First Space Technology and Human Longevity Focused Rolling Fund in Partnership with AngelList - PRNewswire

This entry was posted on December 21, 2020 at 12:57 am and is filed under Longevity. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |